Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07384052 · ClinicalTrials.gov registry record · Phase 1
Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury
A Phase 1 study of Spinal Cord Injury, sponsored by HealthPartners Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07384052: Recruiting Phase 1 study of Spinal Cord Injury, sponsored by HealthPartners Institute.
NCT07384052 is a Phase 1 study of Spinal Cord Injury that is actively recruiting participants, run by HealthPartners Institute. The registered enrollment target is 12 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07384052, a Phase 1 study of Spinal Cord Injury, is actively recruiting participants, sponsored by HealthPartners Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many patient populations, it has not yet been studied in people with spinal cord injury. This study would be the first step to developing insulin nasal spray as a treatment for spinal cord injury in the future. This study is recruiting up to 12 individuals who have experienced a spinal cord injury at least 4 months ago to administer either 76 IU insulin nasal spray or a placebo (inactive nasal spray) at home every day for up to 24 days. Participants will be asked questions about their health and symptoms related their spinal cord injury, and will have their blood collected throughout the study. Participants who are unable to administer the medication independently must have a study partner in order to participate.
Primary Outcome
Total number of AEs/SAEs during the course of treatment. More AEs/SAEs indicates a less safe treatment. AEs counts will include total count and will be stratified by severity.
Conditions Studied
Interventions
- DRUG Regular Insulin
- OTHER 0.9 % Normal Saline
Study Locations (1)
Minnesota
- HealthPartners Neuroscience Center - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT07384052 shows while recruiting
NCT07384052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Regular Insulin is the first listed.
NCT07384052 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07384052 about?
NCT07384052 is a clinical study titled "Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury". The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many pati...
What is the current status of trial NCT07384052?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-02-20. Estimated completion is 2026-09.
What conditions does trial NCT07384052 study?
This clinical trial studies the following conditions: Spinal Cord Injury.
What interventions are being tested in trial NCT07384052?
The interventions under investigation include: Regular Insulin (DRUG), 0.9 % Normal Saline (OTHER).
Who is sponsoring clinical trial NCT07384052?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07384052 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07384052's enrollment target sits among peer trials
12 73rd of 99 higher than 21 of 99 other Spinal Cord Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
RECRUITING · Phase 1
-
CE-STAND: Cervical Epidural STimulation After Neurologic Damage
RECRUITING · Phase 1
-
Platelet-Rich Plasma Therapy for Shoulder Pain in Persons With Spinal Cord Injury
COMPLETED · Phase 1
-
A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
COMPLETED · Phase 1
-
Cortical Recording and Stimulating Array Brain-Machine Interface
RECRUITING · NA
-
Clinical Outcome Assessment for AT & BCI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI